Project Grant R01CA300302
Award Date
6/15/25
Completion Date
5/30/30
Dollars Obligated
$514K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Pensilvania, EE. UU.
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Trustees of the University of Pennsylvania is focused on engineering a protein therapeutic to limit the transformation of the patient's own anti-tumor autoantibodies into highly potent T cell-redirecting antibodies, specifically within the tumor microenvironment. The $216,682 award, effective March 1, 2025 through February 28, 2027, aims to optimize the engineered protein therapeutic...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), provides $698,008 to The Trustees of the University of Pennsylvania to conduct research on the regulation of histone propionylation in pancreatic ductal adenocarcinoma (PDA). The project aims to elucidate the mechanism by which branched-chain amino acid metabolism generates nuclear propionyl-CoA to modulate histone propionylation and gene expression, with the goal...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to understand the fundamental biological mechanisms underlying acute myeloid leukemia (AML). The $483,760 award, effective April 1, 2025 through March 31, 2030, will enable The Trustees of the University of Pennsylvania to investigate the role of the DCAF15 E3 ligase in regulating the cohesin complex and genome architecture in AML. Key objectives include deciphering the...
The National Cancer Institute (NCI) awarded a $2,679,816 Project Grant (CFDA 93.396 Cancer Biology Research) to the Icahn School of Medicine at Mount Sinai. The 5-year grant, effective August 1, 2025, will support an integrated research program focused on understanding the role of mutant p53 proteins in tumor progression, invasion, and metastasis. The program consists of four interrelated projects that will use systematic studies, molecular mechanisms, and transcriptional regulation approaches...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to the University of Texas MD Anderson Cancer Center to conduct research aimed at understanding how mutations in the TP53 tumor suppressor gene drive pro-metastatic interactions between pancreatic cancer cells and the surrounding tumor microenvironment. The $453,304 award will fund a 5-year project focused on clarifying the signaling mechanisms by which mutant TP53 activates the...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $239,991 to The Trustees of the University of Pennsylvania to conduct research aimed at deciphering and modulating chimeric antigen receptor (CAR) T cell persistence and overcoming CAR T cell exhaustion. The key products and services to be delivered under this award include: Development of novel split-engineered CRISPR/dCAS9-guided epigenome editors that can inducibly activate target...
The Project Grant award R35CA293978, provided by the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research), supports research to identify the mechanisms driving rapid evolution of cancer genomes. The $942,442 award to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, MA will fund investigations into two catastrophic mutational processes in cancer, chromothripsis and chromoplexy. The research aims to better understand the mechanisms of chromosome fragmentation, DNA...
This Project Grant award of $153,348, provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program, supports research by The Trustees of Columbia University in the City of New York to dissect the impact of genomic variants on T cell anti-tumor activity. The project aims to define the mechanisms by which PI3K pathway variants modulate T cell function and evaluate their in vivo efficacy in immunotherapy models for melanoma and leukemia, including in...
This Project Grant award of $662,938, provided by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), supports research at Northwestern University to investigate the role of gain-of-function mutant p53 proteins in acute myeloid leukemia (AML). The central objective is to determine how these p53 mutations promote leukemia-initiating cell self-renewal, chromatin accessibility, and 3D chromatin structure, which may contribute to therapy resistance in AML....
This Project Grant award of $673,526 from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) supports research at the University of Pittsburgh to investigate the mechanistic role of p16 loss in regulating zinc homeostasis through the zinc transporter SLC39A9 and its impact on the efficacy of immune checkpoint blockade therapy in melanoma. The research aims to explore whether manipulating zinc levels can enhance the effectiveness of current immune...